J Korean Surg Soc.
2000 Oct;59(4):458-462.
Preliminary Result of Concurrent Chemotherapy and Radiotherapy in Stage I and II Breast Cancer Patients Treated with Breast Conservation Surgery
- Affiliations
-
- 1Department of Surgery, Inje University Sanggye Paik Hospital, Seoul, Korea.
- 2Department of Radiation Oncology, Inje University Sanggye Paik Hospital, Seoul, Korea.
- 3Department of Internal Medicine, Inje University Sanggye Paik Hospital, Seoul, Korea.
Abstract
-
PURPOSE: Breast conserving surgery is increasingly performed in early stage breast cancer patients.
A certain propotion of these patients are at substantial risk for systemic metastasis. However, there is
no valid consensus about optimal sequencing of chemotherapy and radiation therapy. METHODS: We
conducted a randomized prospective study to investigate whether concurrent chemotherapy and radiation
therapy after breast conserving surgery are associated with increased toxicity. Fifty-seven patients with
stage I or II breast cancer were randomly assigned to receive CMF chemotherpy either simultaneously
with (n=37) or before (n=20) radiation therapy. RESULTS: Moist desquamation was the most common
adverse effect which occurred in 46% (16/37) of the patients treated with concurrent chemotherapy and
radiation therapy and 40% (8/20) of those treated with the sequential regimen. This difference between
two groups was not statistically significant. Also the incidence of severe neutropenia (WBC<1,800) or
abnormal elevation of liver enzymes was not influenced by the sequencing of the adjuvant therapies.
Arm edema was observed in 2 patients of the concurrent group and in 2 patients of the sequential
regimen. Two patients treated with the concurrent regimen did not complete 6 cycles of chemotherapy
while only one patient treated with sequential regimen did not. The incidence of toxicity during
chemotherapy was not altered by the timing of radiation therapy. CONCLUSION: Chemotherapy and
radiation therapy can be given concurrently after breast conserving surgery in stage I or II breast cancer
patients without increase in serious toxicity.